AbTherx, a privately held biotechnology company pacing up the discovery of antibodies through innovative technologies, has launched its Next Generation Human Antibody Discovery Platform. AbTherx’s novel transgenic mouse technology, Atlas Mice, includes a clinically validated bispecific antibody format, equivalent to a native antibody, and a long CDR3 antibody, using native human sequences, which improves results against challenging targets such as GPCRs and ion channels. AbTherx is also increasing access to transgenic mice expressing full human antibody diversity.
